In this post in PSI’s “Healthy Lives” blog, “PSI’s Nutrition Research Adviser Dr. Abel Irena talks with Saul Morris, senior program officer at the Bill & Melinda Gates Foundation, about progress that has been made in child health.” Morris addresses treatment for pneumonia, diarrhea, and malaria among children, delivery and access to integrated health systems, the Gates Foundation’s focus on newborn health, and the most effective steps to take to reach the fourth Millennium Development Goal to reduce child mortality by 2015 (5/24).
Pneumonia & Flu
In a letter (.pdf) dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, “has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled,” denying “the agenda was crafted to achieve a predetermined outcome,” the Canadian Press/Winnipeg Free Press writes. Patterson was “responding to a harsh critique of the meeting from Michael Osterholm, a member of the U.S. National Science Advisory Board for Biosecurity [NSABB],” who, in a letter (.doc) to Patterson dated April 12, criticized “the agenda and speakers list” of the March 29-30 meeting, the news service writes (Branswell, 5/4).
“In a long-awaited study that helped prompt a contentious debate over the wisdom of conducting research that has the potential to help as well as harm, scientists reported Wednesday that they had engineered a mutant strain of [H5N1] bird flu that can spread easily between ferrets — a laboratory animal that responds to flu viruses much as people do,” the Los Angeles Times (Brown, 5/3). Published in the journal Nature, the study is “the first of two controversial papers about laboratory-enhanced versions of the deadly bird flu virus that initially sparked fears among U.S. biosecurity experts that it could be used as a recipe for a bioterrorism weapon,” Reuters writes (Steenhuysen, 5/2). The U.S. National Security Advisory Board on Biosecurity “had asked journals to hold off publishing” the studies, but “[t]he panel later dropped its objections after it became clear the engineered viruses were less virulent than had been feared,” according to the Washington Post (Brown, 5/2).
“The Dutch government has agreed to grant an export license to allow Ron Fouchier, a virologist at the Erasmus Medical University in Rotterdam, to publish his work on H5N1 avian influenza in Science,” Nature’s “News Blog” reports (Owens, 4/27). “Fouchier had to get permission first from the Dutch Department of Economic Affairs, Agriculture and Innovation — in line with E.U. regulations — because a risk existed that the H5N1 virus, as well as its research, ‘could be used for the wrong purposes,’ the Dutch department said in a statement,” according to Agence France-Presse (4/28).
In a Huffington Post Blog opinion piece, Orin Levine, executive director of the International Vaccine Access Center (IVAC), describes watching the suffering of an infant with severe pneumonia and his parents while in Ghana on Thursday, writing that the experience was “a personal reminder as to why our work to prevent disease is so perilous, and why disease control so promising in Africa.” Noting that last year in Ghana, “approximately 50,000 young children — nearly seven out of every 100 — died before their fifth birthday,” Levine adds, “I also saw the promise of prevention in Ghana,” with the launch of an immunization campaign to provide both pneumococcal and rotavirus vaccines. With support from the GAVI Alliance, Ghana is the first country in Africa to introduce two new vaccines against pneumonia and diarrhea at the same time,” he notes.
“[T]he controversy over the research into the genetic modification of the H5N1 flu virus, finally approved for publication, should offer a reminder of the importance of debate” over dual-use technology, a Nature editorial states. “[D]ual-use basic research is a special case because its implications, for good and bad, are often viewed with the greatest clarity by only a small minority of people,” and often only “[t]he scientists involved (and they are increasingly specialists in very small fields) … can fully understand the risks posed by a line of research,” according to the editorial. “There are disadvantages to leaving it up to outsiders to initiate debate about risks, benefits and ethics,” the editorials states, noting three disadvantages, including the risk of misconceptions and a lack of knowledge about how to handle some research.
“This week, a Senate panel is investigating biological security in the wake of” controversial “potentially dangerous research” on H5N1 avian influenza, “with good reason,” Rep. Jim Sensenbrenner (R-Wisc.) writes in a Washington Times opinion piece. He says “the U.S. government should not have been caught by surprise” by the two research papers describing how genetic mutations to the virus could make it transmissible between ferrets, because the National Science Advisory Board for Biosecurity (NSABB) “was created in 2004 and charged with the specific responsibility of reviewing this type of research and offering guidance to all federal agencies that conduct biological research.” Sensenbrenner says the NSABB’s initial recommendation against publishing the studies and its subsequent reversal of that decision has left him with “suspicions that the U.S. government is woefully unprepared for dealing with dual use research of concern — research that, while conducted for a legitimate scientific purpose, could be dangerous if misused.”
Ron Fouchier of Erasmus Medical Center, “[t]he Dutch scientist at the center of the controversy over recent bird flu experiments, says that his team applied for government permission today to submit a paper describing their research to a science journal,” NPR’s health blog “Shots” reports, adding, “The Dutch government has asserted that the studies, which describe how to make bird flu virus more contagious, fall under regulations that control the export of weapons technology.” According to the news service, “He feels the government’s actions amount to censorship and has previously has said he did not want to apply for an export permit, because it would set a precedent” (Greenfieldboyce, 4/24). “Fouchier says that by conceding to the government’s request while continuing to contest the need for an export permit, he hopes to have found an acceptable compromise,” Nature writes.
Rep. Sensenbrenner Sends Second Letter Inquiring About U.S. Government’s Review Of Controversial H5N1 Studies
“A senior Republican in the U.S. House of Representatives is asking more questions about how the U.S. government reviewed two controversial H5N1 avian influenza studies, and how it wrote a new policy for reviewing taxpayer-funded studies that might be used for good and evil,” ScienceInsider reports. Rep. Jim Sensenbrenner (R-Wisc.) on Monday “sent a letter [.pdf] to Francis Collins, director of the National Institutes of Health (NIH), asking him to clarify how the National Science Advisory Board for Biosecurity (NSABB) reached its recent decision to recommend publication of the two studies after recommending against publication late last year,” the news service writes, noting, “The letter also asks for more information on which government officials were involved” in the new policy regarding research that might be “dual use research of concern” (DURC).
The U.S. government on Friday formally accepted a recommendation from the National Science Advisory Board for Biosecurity (NSABB) “to publish two controversial studies of the H5N1 avian influenza virus, moving the pair of papers another step closer to publication,” ScienceInsider reports (Malakoff, 4/20). “Groups led by the two scientists — Yoshihiro Kawaoka of the University of Wisconsin and Ron Fouchier of Erasmus Medical Center in Rotterdam — engineered the H5N1 virus to be more transmissible between ferrets, mammals whose response to the flu is most like humans,” Bloomberg Businessweek notes. “The research is critical to understanding and detecting bird flu strains, Health and Human Services Secretary Kathleen Sebelius and Francis Collins, director of the National Institutes of Health, said [on Friday] in a statement,” Bloomberg writes, noting that the NSABB “recommended in March that Sebelius and Collins approve publication” (Wayne, 4/20).